Adverse Effects Associated With JAK Inhibitors in Myelofibrosis

Following rare CRS and ICANS incidence following CAR T-cell therapy, investigators propose a reduced 2-week monitoring period with extensions as needed.

Experts discuss updated findings presented at the 2024 EHA Congress in diseases such as mantle cell lymphoma and acute myeloid leukemia.

Researchers at the Mayo Clinic have found that mesenchymal stromal cells engineered with chimeric antigen receptors can enhance immunosuppression in the context of immune-related disorders.

The first episode of CancerNetwork's podcast Oncology Peer Review On-The-Go explores disparities in cancer care treatment among minorities and the significance of a representative sample in clinical trials.

Frontline acalabrutinib plus bendamustine/rituximab may become a new standard therapy in MCL, according to Michael Wang, MD.

Approved for use in newly diagnosed and previously treated myelofibrosis, momelotinib may addresses key manifestations of the disease.